Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer By Alice GoodmanDecember 10, 2019 Shanu Modi, MD In the post-trastuzumab era, a number of U.S. Food and Drug Administration (FDA)-approved targeted agents for metastatic HER2-positive breast cancer are available, but…
In an interim analysis of a phase III noninferiority trial (COLLISION) reported in The Lancet Oncology, van der Lei et al found that thermal ablation…
Are patients enrolled in Medicare Advantage more or less likely to be prescribed high-cost drugs for cancer treatment compared with traditional Medicare? A new study…
Final data from the phase III TALAPRO-2 study show a significant improvement in overall survival in men with metastatic prostate cancer treated with a combination…
A recent ASCO survey measuring the impact of professional well-being and satisfaction on career plans among oncologists in the United States revealed a higher rate…
As reported in the Journal of Clinical Oncology by Yamamoto et al, the final overall survival analysis of the Japanese phase III PRECIOUS study showed…
Patients with ERBB2-positive breast cancer and central nervous system (CNS) metastases only vs concomitant extracranial metastases have been found to experience longer overall survival but…
The results from the phase III FIRE-4 randomized clinical trial showed that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type-mutated metastatic colorectal cancer.…
As reported in the Journal of Clinical Oncology by Sands et al, the phase II TROPION-Lung05 trial showed “encouraging activity” of datopotamab deruxtecan in patients…
Platinum-based drugs, taxanes, and lung cancer seem to be associated with the highest rates of persistent painful neuropathy, defined as lasting at least 3 months.
In an interim analysis of a phase III noninferiority trial (COLLISION) reported in The Lancet Oncology, van der Lei et al found that thermal ablation…
